BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $33
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Illumina (ILMN)
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $25
Truist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $25
Scotiabank Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $41
H.C. Wainwright Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $40
Optimistic Buy Rating for Keros Therapeutics Driven by Promising Pipeline and Trial Results
Keros Therapeutics Price Target Maintained With a $15.00/Share by Wedbush
Keros Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $40 Price Target
Scotiabank Remains a Buy on Keros Therapeutics (KROS)
Mixed Signals for Keros Therapeutics: Promising Data and Safety Concerns Lead to Hold Rating
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $33
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $15 to $40
Keros Therapeutics Is Maintained at Overweight by Wells Fargo
Keros Therapeutics Hold Rating: Uncertainty in KER-065 Development and Cibotercept Safety Concerns
H.C. Wainwright Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Oneview Healthcare Chess Depository Interests Repr 1 (OtherONVVF) and Teladoc (TDOC)